{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:12:23Z","timestamp":1793923943969,"version":"4.8.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.metabol.2014.10.027","type":"journal-article","created":{"date-parts":[[2014,10,30]],"date-time":"2014-10-30T05:54:22Z","timestamp":1414648462000},"page":"S16-S21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":228,"special_numbering":"S1","title":["Biomarkers for personalized oncology: recent advances and future challenges"],"prefix":"10.1016","volume":"64","author":[{"given":"Madhu","family":"Kalia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2014.10.027_bb0005","series-title":"Facts and figures","author":"American Cancer Society","year":"2014"},{"issue":"8","key":"10.1016\/j.metabol.2014.10.027_bb0010","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1200\/JCO.2012.45.3753","volume":"31","author":"Li","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.metabol.2014.10.027_bb0015","author":"National Cancer Institute"},{"issue":"1","key":"10.1016\/j.metabol.2014.10.027_bb0020","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000334825","article-title":"Recent developments and future perspectives of personalized oncology","volume":"35","author":"Grullich","year":"2012","journal-title":"Onkologie"},{"key":"10.1016\/j.metabol.2014.10.027_bb0025","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s40291-013-0077-9","article-title":"Prognostic and predictive biomarkers: tools in personalized oncology","volume":"18","author":"Nalejska","year":"2014","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.metabol.2014.10.027_bb0030","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/emmm.201000070","article-title":"Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine","volume":"2950","author":"Dias-Santagata","year":"2010","journal-title":"EMBO Mol Med"},{"issue":"2","key":"10.1016\/j.metabol.2014.10.027_bb0035","first-page":"70","article-title":"Application of high-throughput technologies in cancer molecular diagnostics","volume":"9","author":"Poznanski","year":"2013","journal-title":"Oncol Clin Pract"},{"key":"10.1016\/j.metabol.2014.10.027_bb0040","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2174\/15680096113139990089","article-title":"Use of single nucleotide polymorphism array technology to omprove the identification of chromosomal lesions in leukemia","volume":"13","author":"Iacobucci","year":"2013","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.metabol.2014.10.027_bb0045","first-page":"85","article-title":"Choromosome studies on normal and leukemic human leukocytes","volume":"25","author":"Nowell","year":"1960","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.metabol.2014.10.027_bb0050","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/bjh.12364","article-title":"MicroRNAs in myleoid malignancies","volume":"162","author":"Gordon","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.metabol.2014.10.027_bb0055","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.1073\/pnas.84.18.6558","article-title":"In vitro transformation of immature hematopoetic cells by the P210 BCR\/ABL oncogene product of the Philadelphia chromosome","volume":"84","author":"McLaughin","year":"1987","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.metabol.2014.10.027_bb0060","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.metabol.2014.10.027_bb0065","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.metabol.2014.10.027_bb0070","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","article-title":"Patients with chronic myeloid leukemia who maintain a complete response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR","volume":"24","author":"Ross","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.metabol.2014.10.027_bb0075","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.metabol.2014.10.027_bb0080","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.3109\/10428194.2013.772607","article-title":"Surrogate end points for long-term outcomes in chronic myeloid leukemia","volume":"54","author":"Akwaa","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.metabol.2014.10.027_bb0085","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1177\/009127000004001212","article-title":"Optimizing the use of biomarkers, surrogate endpoints and clinical end points for more efficient drug development","volume":"40","author":"Colburn","year":"2000","journal-title":"Clin Pharmacol"},{"key":"10.1016\/j.metabol.2014.10.027_bb0090","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2012.104","article-title":"Standardized definitions of molecular response in chronic myeloid leukemia","volume":"26","author":"Cross","year":"2012","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.metabol.2014.10.027_bb0095","first-page":"819","article-title":"Continued therapeutic response monitoring in optimal responders with CML","volume":"10","author":"Branford","year":"2012","journal-title":"Curr Adv Hematol Oncol"},{"issue":"1","key":"10.1016\/j.metabol.2014.10.027_bb0100","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/1078155212474047","article-title":"Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal and non-small cell lung cancers: a systematic review of current development, evidence, and recommendation","volume":"20","author":"Chung","year":"2014","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.metabol.2014.10.027_bb0105","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.1999.17.5.1474","article-title":"Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer","volume":"17","author":"Harvey","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.metabol.2014.10.027_bb0110","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1200\/JCO.2010.28.4273","article-title":"Genomic index of sensitivity to endocrine therapy for breast cancer","volume":"28","author":"Symmans","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.metabol.2014.10.027_bb0115","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/1040-8428(94)00144-I","article-title":"Epidermal growth factor-related peptides and their receptors in human malignancies","volume":"19","author":"Salomon","year":"1995","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.metabol.2014.10.027_bb0120","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","article-title":"Randomized study of lapatinib alone or in combination with trastuzumab in women with ErB-2 positive, trasuzumab-refractory metastatic breast cancer","volume":"28","author":"Blackwell","year":"2010","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2014.10.027_bb0125","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000334823","article-title":"The role of molecular diagnostics in cancer diagnosis and treatment","volume":"35","author":"Ozretic","year":"2012","journal-title":"Onkologie"},{"key":"10.1016\/j.metabol.2014.10.027_bb0130","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1158\/1055-9965.EPI-10-0437","article-title":"Global patterns of cancer incidence and mortality rates and trends","volume":"19","author":"Jemal","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.metabol.2014.10.027_bb0135","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1200\/JCO.2012.43.1825","article-title":"Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer","volume":"30","author":"Heuckmann","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.metabol.2014.10.027_bb0140","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s13277-013-0759-2","article-title":"The war on cancer; are we winning?","volume":"34","author":"Duffy","year":"2013","journal-title":"Tumor Biol"},{"key":"10.1016\/j.metabol.2014.10.027_bb0145","article-title":"Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?","author":"Rossi","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.metabol.2014.10.027_bb0150","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1200\/JCO.2012.43.1858","article-title":"Timing of epidermal growth factor receptor tyrosine kinase inhibitor therpy in patients with lung cancer with EGRF mutations","volume":"30","author":"Moran","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.metabol.2014.10.027_bb0155","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ctrv.2011.10.003","article-title":"EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects","volume":"38","author":"Soria","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.metabol.2014.10.027_bb0160","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-1-62703-727-3_4","article-title":"Advances in adjuvant therapy:potential for prognostic and predictive biomarkers","volume":"1102","author":"Davar","year":"2014","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.metabol.2014.10.027_bb0165","first-page":"v","article-title":"Preface. Molecular diagnostics for melanoma: methods and protocols","volume":"1102","author":"Thurin","year":"2014","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.metabol.2014.10.027_bb0170","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cllc.2012.05.004","article-title":"Algorithim for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity","volume":"13","author":"Gandara","year":"2012","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.metabol.2014.10.027_bb0175","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.cell.2011.03.026","article-title":"The evolving war on cancer","volume":"145","author":"Haber","year":"2011","journal-title":"Cell"},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2014.10.027_bb0180","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.metabol.2012.08.016","article-title":"Personalized oncology: recent advances and future challenges","volume":"62","author":"Kalia","year":"2013","journal-title":"Metabolism"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049514003369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049514003369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:04:39Z","timestamp":1758427479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049514003369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0026049514003369"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2014.10.027","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarkers for personalized oncology: recent advances and future challenges","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2014.10.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}